Even After Settling Claims, These Doctors Continue to Practice
A vascular doctor is still practicing after many years of investigations by regulators and disciplinary measures by medical boards in many states. A ProPublica report has found gaps in the system that protects patients from doctors who put them at risk. ProPublica investigated vascular medicine, an area ripe for fraud and misconduct related to Medicare billing. Additionally, federal investigators have found that some doctors continue to practice after complaints of performing unnecessary procedures or misconduct claims.
ACA Marketplace Insurers Say Rates to Rise Because of Inflation, Prescription Drugs
ACA Marketplace insurers are requesting a median premium increase of 6% for 2024, according to a new KFF analysis of the preliminary rate filings. Insurers cite price increases for medical care and prescription drugs as a key driver of premium growth in 2024, according to KFF’s examination of publicly available documents from 58 insurers.
Mental Health Issues and Obesity Rise as Children with Autism Age
The prevalence of sleep disorders, mental health issues and obesity/cholesterol increase as children with autism become adults, according an article in Spectrum. Practitioners say, and a recent study has found, that those with autism have a higher prevalence of most medical conditions, including seizures, obesity and diabetes, gastrointestinal and sleep disorders, as well as mental issue issues.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
2 Commerce Drive
Cranbury, NJ 08512